An Observational Study Measuring Outcomes in Cancer Patients Treated for Moderate to Severe Hyponatremia in Italy (ASSERT)
A Prospective, Observational Study Measuring Sodium Improvement and Outcomes in Cancer Patients Treated for Moderate to Severe Hyponatremia Secondary to SIADH in Italy
Sponsor: Otsuka Pharmaceutical Europe Ltd
A observational or N/A phase clinical study on Cancer and Hyponatremia, this trial is completed. The trial is conducted by Otsuka Pharmaceutical Europe Ltd and has accumulated 9 data snapshots since 2015. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
9 versions recorded-
Sep 2024 — Present [monthly]
Completed
-
Jul 2024 — Sep 2024 [monthly]
Completed
-
Jan 2021 — Jul 2024 [monthly]
Completed
-
Jun 2018 — Jan 2021 [monthly]
Completed
-
May 2018 — Jun 2018 [monthly]
Completed
Status: Recruiting → Completed
▶ Show 4 earlier versions
-
Apr 2018 — May 2018 [monthly]
Recruiting
Phase: NA → None
-
Aug 2017 — Apr 2018 [monthly]
Recruiting NA
-
Feb 2017 — Aug 2017 [monthly]
Recruiting NA
-
Jan 2017 — Feb 2017 [monthly]
Recruiting NA
First recorded
Oct 2015
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Otsuka Pharmaceutical Europe Ltd
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Ancona, Italy , Aosta, Italy , Bari, Italy , Cagliari, Italy , Cosenza, Italy , Florence, Italy , Genova, Italy , Messina, Italy , Milan, Italy , Napoli, Italy and 10 more locations